HIND supply chain intelligence for Vyome Holdings, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Vyome Holdings, Inc. (HIND) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MAXIM-GROUP-LLC | MAXIM-GROUP-LLC | 92% | The Company entered into Amendment No. 1 to the Equity Distribution Agreement dated May 30, 2025 (the “Sales Agreement” or “ATM”) with Maxim Group LLC ("Maxim") to act as the Company’s exclusive sale… |
| REMUS-CAPITAL-SERIES-B-II-L-P | REMUS-CAPITAL-SERIES-B-II-L-P | 92% | the Buyer will acquire senior secured convertible notes in the aggregate principal amount of $5,765,000 issued by Humanyze and held by Remus |
| HUMANYZE | HUMANYZE | 85% | Remus will have the right to appoint one director to the LICH board immediately after closing. The LICH board and CEO will use their best efforts to raise capital as needed. As a condition to closing… |
| SNYNF | Sanofi | 72% | or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or inval… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from HIND graph: or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination i… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HUMANYZE | HUMANYZE | 90% | following the Closing, Remus agreed to ensure that Humanyze remains active and in good standing for purposes of servicing select existing debts, liabilities, and other obligations |
| SUN-PHARMA | SUN-PHARMA | 90% | various licensing agreements with Sun Pharma |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from HIND graph: t such party. Costly and time- consuming litigation could be necessary to enforce and determine the scope of our pro… |
| SNYNF | Sanofi | 72% | t such party. Costly and time- consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adv… |
| THCH | TH International Limited | 72% | nti-fungal product in India, whereby the Company will receive a net service fee payment for sales of such products made by Sun Pharma. This agreement terminated in 2024. The Company had also entered … |
| THCH | TH International Limited | 72% | Reciprocal relationship from THCH graph: Reciprocal relationship from HIND graph: nti-fungal product in India, whereby the Company will receive a net service fee payment for sales of such products ma… |
| COMPANY-RAIDER-LIFESCIENCES-INC | COMPANY-RAIDER-LIFESCIENCES-INC | 62% | nti-fungal product in India, whereby the Company will receive a net service fee payment for sales of such products made by Sun Pharma. This agreement terminated in 2024. The Company had also entered … |
| IMPETIS-BIOSCIENCES-LIMITED | IMPETIS-BIOSCIENCES-LIMITED | 62% | 19 - 144,419 ( 94,976 ) - ( 94,976 ) Net income $ ( 953,892 ) $ ( 31,629 ) $ ( 985,521 ) $ ( 410,473 ) $ 116,499 $ ( 293,974 ) Assets of segment $ 10,185,137 $ 309 $ 10,185,446 $ 1,293,784 $ 149,299 … |
| INDIA-VYOME-THERAPEUTICS-LIMITED | INDIA-VYOME-THERAPEUTICS-LIMITED | 62% | utics, Inc. (“VTI”), a Delaware corporation, and its subsidiary in India, Vyome Therapeutics Limited (“VTL”) and are collectively referred to as “Vyome”. VTI signed a definitive merger agreement (“Me… |
| OTC-MARKETS-GROUP | OTC-MARKETS-GROUP | 62% | and related allowances for depreciation and amortization are eliminated from the accounts, and any resulting gain or loss is reflected in operations. 8 i) Goods and Service Tax and Other Credits Rece… |
| VYOME-LIMITED | VYOME-LIMITED | 62% | nti-fungal product in India, whereby the Company will receive a net service fee payment for sales of such products made by Sun Pharma. This agreement terminated in 2024. The Company had also entered … |
| VYOME-THERAPEUTICS-INC | VYOME-THERAPEUTICS-INC | 62% | nti-fungal product in India, whereby the Company will receive a net service fee payment for sales of such products made by Sun Pharma. This agreement terminated in 2024. The Company had also entered … |
| VYOME-THERAPEUTICS-LIMITED | VYOME-THERAPEUTICS-LIMITED | 62% | nti-fungal product in India, whereby the Company will receive a net service fee payment for sales of such products made by Sun Pharma. This agreement terminated in 2024. The Company had also entered … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| HIND-DEBT-3753 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| HIND-DEBT-3752 | Warrants outstanding: 6008589 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| HIND-DEBT | Debt stack $10.0M | 90% | Market cache reports total debt of $10.0M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| HIND-OWNER-UBS-GROUP-AG | UBS Group AG | 95% | 13F/ownership overlay lists UBS Group AG; shares held 3,959; ownership 0.07%; value $8,670; as of 2025-12-31. |
| HIND-OWNER-KOVITZ-INVESTMENT-GROUP-PARTNERS-LLC | Kovitz Investment Group Partners, LLC | 95% | 13F/ownership overlay lists Kovitz Investment Group Partners, LLC; shares held 14,640; ownership 0.26%; value $32,061; as of 2025-09-30. |
| HIND-OWNER-BANK-OF-AMERICA-CORPORATION | Bank of America Corporation | 95% | 13F/ownership overlay lists Bank of America Corporation; shares held 6; value $13; as of 2025-09-30. |
| HIND-OWNER-HIGHTOWER-ADVISORS-LLC | HighTower Advisors, LLC | 95% | 13F/ownership overlay lists HighTower Advisors, LLC; shares held 17,973; ownership 0.32%; value $39,360; as of 2025-09-30. |
| HIND-OWNER-MORGAN-STANLEY | Morgan Stanley | 95% | 13F/ownership overlay lists Morgan Stanley; shares held 118; value $258; as of 2025-09-30. |
| HIND-OWNER-ROYAL-BANK-OF-CANADA | Royal Bank of Canada | 95% | 13F/ownership overlay lists Royal Bank of Canada; shares held 5,856; ownership 0.10%; value $12,824; as of 2025-09-30. |
| HIND-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 12,195; ownership 0.22%; value $26,707; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| SNYNF | Sanofi | 100.00 | 1 | ['customer', 'supplier'] |
| VINP | Vinci Compass Investments Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 50.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 50.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 50.00 | 2 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 50.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 50.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 50.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 50.00 | 2 | |
| AZN | AstraZeneca PLC | 50.00 | 2 | |
| CLDX | Celldex Therapeutics, Inc. | 50.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 50.00 | 2 | |
| LGND | Ligand Pharmaceuticals Incorporated | 50.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 50.00 | 2 | |
| FULC | Fulcrum Therapeutics, Inc. | 50.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 50.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 50.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 50.00 | 2 |